Sign in to view content

Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials

Katherine E Talcott, MD

Video
Published 2021

Related

Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial
Eric W Schneider, MD
Annual Meeting Talks
2023
Association of Ultra-Widefield Fluorescein Angiography-identified Retinal Nonperfusion With Risk of Diabetic Retinopathy Worsening Over Time
Paolo Antonio S. Silva, MD
Annual Meeting Talks
2022
Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy The Phase II ALTITUDE Study
Dilsher S. Dhoot, MD
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more